AngioDynamics, with its disruptive and innovative medical devices, addresses unmet patient needs by elevating the standard of care for chronic and acute disease states in vascular, peripheral vascular, and oncology medicine.
These devices provide healthcare professionals around the world with the vital tools they need to deliver high-quality patient care and improve patient outcomes.
Each day, AngioDynamics and its employees earn the trust of patients and the medical community by being a committed partner that continuously focuses on delivering safer, clinically-relevant and economically-favorable solutions that help improve patient outcomes.
AngioDynamics Reports Fiscal 2019 Fourth Quarter and Full-Year Financial Results
AngioDynamics to Report Fiscal 2019 Fourth Quarter and Full-Year Financial Results on July 10, 2019
American Urological Association
Date: 03 May, 2019
Time:
Location: Chicago, IL
AngioDynamics to Present at the Raymond James Life Sciences and MedTech Conference
AngioDynamics Completes Sale of NAMIC® Fluid Management Portfolio to Medline Industries, Inc.
Fiscal 2019 Fourth Quarter HighlightsNet sales of $96.3 million, an increase of 9.0% year over year and 5.2% organicallyGross margin of 53.6%, flat year-over-yearGAAP EPS of $1.54 per ...
AngioDynamics® history is best characterized by innovation and growth. Originally founded in Queensbury, N.Y., U.S., in 1988, AngioDynamics has grown into a NASDAQ-listed public company with a global reach.
USA
International